<DOC>
	<DOCNO>NCT00044876</DOCNO>
	<brief_summary>Uterine leiomyomata ( fibroid ) common benign tumor uterine muscle premenopausal woman . These tumor may cause bleeding , pelvic pain pressure . Because fibroid grow presence estrogen , medical therapy decrease estrogen level ( like GnRH analog ) cause fibroid shrink may relieve symptom . However , medication give short-term inconvenient side effect hot-flushes . Thus , many woman symptomatic fibroid choose remove surgically , either individually remove uterus via hysterectomy . The study evaluate new medical treatment fibroid use progesterone receptor modulator CDB-2914 . A similar compound , mifepristone ( Registered Trademark ) , reduce fibroid size give twelve week . This study compare fibroid size , hormone level symptoms daily administration CDB-2914 ( 10 25 mg ) placebo 10 - 14 week . To , woman undergo MRI saline hysterosonogram ( ultrasound fluid ) uterus end treatment ; blood drawn every 7 - 14 day , fill symptom calendar home . Hysterectomy perform end treatment evaluate effect medication uterine fibroid tissue , provide treatment study participant . Women randomly assign treatment group ; treatment period neither participant investigator know type treatment woman receive .</brief_summary>
	<brief_title>Treatment Uterine Fibroids With CDB-2914 , Experimental Selective Progesterone Receptor Antagonist</brief_title>
	<detailed_description>Uterine leiomyomata ( fibroid ) common benign tumor uterine muscle premenopausal woman . These tumor may cause bleeding , pelvic pain pressure . Because fibroid grow presence estrogen , medical therapy decrease estrogen level ( like GnRH analog ) cause fibroid shrink may relieve symptom . However , medication give short-term inconvenient side effect hot-flushes . Thus , many woman symptomatic fibroid choose remove surgically , either individually remove uterus via hysterectomy . The study evaluate new medical treatment fibroid use progesterone receptor modulator CDB-2914 . A similar compound , mifepristone ( Registered Trademark ) , reduce fibroid size give twelve week . This study compare fibroid size , hormone level symptoms daily administration CDB-2914 ( 10 25 mg ) placebo 10 - 14 week . To , woman undergo MRI saline hysterosonogram ( ultrasound fluid ) uterus end treatment ; blood drawn every 7 - 14 day , fill symptom calendar home . Hysterectomy perform end treatment evaluate effect medication uterine fibroid tissue , provide treatment study participant . Women randomly assign treatment group ; treatment period neither participant investigator know type treatment woman receive .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>GENERAL INCLUSION CRITERIA : Women receive insulin thyroid hormone replacement may participate wellcontrolled ; use vitamins calcium RDA allow . Female genderto evaluate effect target population clinical trial . In good health . Chronic medication use acceptable except glucocorticoid use . Other chronic medication use may acceptable discretion research team . Interval use overthe counter drug acceptable must record . Menstrual cycle 24 35 day . Hemoglobin great 10 g/dL . Willing able comply study requirement . Age 33 50 . Using mechanical ( condom , diaphragm ) , sterilization abstinence method contraception duration study . Negative urine pregnancy test . BMI le equal 33 . Able read speak English fluently allow accurate selfadministration medication , record symptom unassisted completion questionnaire . Normal glomerular filtration rate . Liver function test within 130 % upper limit . INCLUSION CRITERIA FOR WOMEN WITH LEIOMYOMA : History uterine leiomyoma cause symptom bleed , pressure , pain , define ACOG practice bulletin ( ACOG Practice Bulletin 1994 ) : Excessive uterine bleeding evidence either followingprofuse bleed flood clot repetitive period last 8 day ; anemia due acute chronic blood loss ; OR Pelvic discomfort cause leiomyomata , either acute severe chronic low abdominal low back pressure bladder pressure urinary frequency due urinary tract infection . Uterine leiomyoma ( ta ) least 2 cm size . No desire fertility ; willing undergo hysterectomy . GENERAL EXCLUSION CRITERIA : Significant abnormality history , physical laboratory examination . Pregnancy . Lactation . Use oral , injectable inhaled glucocorticoid megesterol within last year . Unexplained vaginal bleeding . History malignancy within past 5 year . Use estrogen progesteronecontaining compound , oral contraceptive hormone replacement therapy , within 8 week study entry , include transdermal , injectable , vaginal oral preparation . Use agent know induct hepatic P450 enzyme ; use imidazole . Current use GnRH analog compound affect menstrual cyclicity . FSH great 20 IU/mL . Significant medical disorder . Cervical dysplasia . Need interval use narcotic . Abnormal adnexal/ovarian mass . Intrauterine device . EXCLUSION CRITERIA FOR WOMEN WITH FIBROIDS : Use herbal medication estrogenic antiestrogenic effect within past 3 month . Contradiction anesthesia Genetic cause leiomyomata . Previous participation study . Known recent rapid growth fibroid , define double size six month .</criteria>
	<gender>Female</gender>
	<minimum_age>33 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 1, 2015</verification_date>
	<keyword>Endometrium</keyword>
	<keyword>Progesterone</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Leiomyoma</keyword>
	<keyword>Uterine Leiomyoma</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>Fibroids</keyword>
</DOC>